AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-K$LABT

Lakewood-Amedex Biotherapeutics Inc. (LABT): Entry into a Material Definitive Agreement

Lakewood-Amedex Biotherapeutics Inc. (LABT) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Lakewood-Amedex Biotherapeutics Announces Completion of Series C Convertible Preferred Stock Redemption SARASOTA, Fla., November 5, 2026 – Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) (the “Company”), a clinical-stage biotechnology company advancing a novel cl

Event · Buyback
Original reporting
SEC EDGAR 8-K
Published Nov 10, 2026, 10:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 10:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefCorporate actions
Primary signal
$LABT
Neutral
high confidence
Mentioned
$LABT
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$LABTNeutralLow
01

Why it matters

Redemption clears the capital structure, removing conversion dilution and financing covenants tied to the preferred shares.

02

Market read

The transaction is a modest corporate action for a microcap biotech, offering limited but clear implications for equity holders.

03

What to watch

Future financing needs may still require equity or debt, and the redemption does not guarantee improved liquidity.

Relevance 6/10Novelty 5/10Timing: post-market today

Background

Lakewood-Amedex Biotherapeutics is a clinical-stage biotech developing broad-spectrum antimicrobials. The Series C Preferred Stock carried conversion rights that could dilute existing shareholders.

Company-level read

Ticker impact

$LABTNeutralHigh confidence
Context

Lakewood-Amedex Biotherapeutics completed redemption of its Series C Convertible Preferred Stock, removing all preferred shares and related restrictions.

Expected impact

likely modest upside as investors view the reduced dilution and clearer equity base positively.

Evidence & confidence

The redemption removes conversion risk and financing restrictions, improving financial flexibility without adding new cash.

Market effects

Sector

May be viewed positively for biotech small-caps focusing on capital structure optimization.

Regional

Limited to U.S. biotech investors.

Global

Minimal global impact.

Counterpoint

What could challenge this read

The cash used for redemption could have been deployed to fund R&D, potentially slowing pipeline progress.

Key entities

  • Company
    Lakewood-Amedex Biotherapeutics Inc.

    Clinical-stage biotech focused on antimicrobial therapeutics.

  • Counterparty
    Shakawe Capital LLC

    Entered redemption agreement with Lakewood-Amedex.

Read at source← All news

Related articles

$LABTMedAI 8/10

A compound inhibited up to 97% of E. coli growth in rodents; the control group showed no effect.

Lakewood-Amedex Biotherapeutics (LABT) reported preclinical data showing its Bisphosphocin compound Nu-8 inhibited up to 97% of E. coli growth in rodents. Aerosol formulations also showed activity against pulmonary infections. The company plans further development to identify a clinical candidate. Nu-3 is in a Phase 2a trial for diabetic foot ulcers, with topline data expected in Q1 2027.

stocktitan.net
$LABTMedAI 8/10

Lakewood-Amedex Biotherapeutics Announces Positive Preclinical Data in Urinary Tract and Pulmonary Infection Indications with Bisphosphocin® Compounds

Lakewood-Amedex Biotherapeutics reported positive preclinical data for its Bisphosphocin® compounds, showing up to 97% inhibition of E. coli growth in urinary tract infections and activity against resistant bacteria in pulmonary infections. The company's lead candidate, Nu-3, is in a Phase 2a trial for diabetic foot ulcers, with results expected in Q1 2027. The Bisphosphocin® class aims to combat antibiotic-resistant strains.

prnewswire.com
$LABTMedAI 8/10

Lakewood-Amedex doses first patient in Phase 2a trial for Diabetic foot infections

Lakewood-Amedex Biotherapeutics dosed the first patient in a Phase 2a trial for Nu-3, a gel treating mildly infected diabetic foot ulcers. The trial will assess safety, efficacy, and optimal dosage. Results are expected in Q1 2027, with potential Phase 2b advancement if successful. According to the company, Nu-3 aims to reduce antimicrobial resistance by targeting infections locally.

proactiveinvestors.com
$LABTLow

Lakewood-Amedex Biotherapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of Nu-3 for Infected Diabetic Foot Ulcers

Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) has dosed the first patient in its Phase 2a clinical trial for Nu-3, a topical antimicrobial gel for infected diabetic foot ulcers. The trial aims to evaluate safety and efficacy of three gel concentrations, with topline data expected in Q1 2027. Nu-3 is part of the company's Bisphosphocin® antimicrobial platform.

prnewswire.com
$LABTMedAI 8/10

Lakewood-Amedex Biotherapeutics Announces IRB Approval and Clinical Site Readiness to Initiate Phase 2a Clinical Trial of Nu-3 for the Treatment of Infected Diabetic Foot Ulcers

Lakewood-Amedex Biotherapeutics (NASDAQ: LABT) received IRB approvals and clinical site readiness to start a Phase 2a trial for its lead product, Nu-3, treating infected diabetic foot ulcers. The trial aims to evaluate Nu-3's safety and efficacy, building on positive preclinical data. The company aims to address antibiotic-resistant bacterial strains with its Bisphosphocin® class of antimicrobials.

insidermonkey.com